Loading
For uterine carcinosarcoma, the standard breast and ovarian regimen carboplatin-paclitaxel was as effective as the older, more toxic paclitaxel-ifosfamide combination, simplifying treatment of this rare aggressive cancer.
Phase 3 non-inferiority trial of 536 patients with stage I to IV, persistent or recurrent uterine carcinosarcoma (with a small ovarian carcinosarcoma cohort) randomised to paclitaxel-carboplatin or paclitaxel-ifosfamide.
Median overall survival was 37 versus 29 months (hazard ratio 0.87, non-inferior) and progression-free survival 16 versus 12 months, with more haematological toxicity but less confusion and genitourinary toxicity with carboplatin.
Carboplatin-paclitaxel is the chemotherapy standard for uterine carcinosarcoma in all stages, now combined with dostarlimab in advanced disease following RUBY, which included carcinosarcoma.
Shares Ifosfamide, Journal of Clinical Oncology.
Shares Uterine carcinosarcoma, Journal of Clinical Oncology.
Shares Ifosfamide, Carboplatin.
Shares Ifosfamide, Carboplatin.
Shares Ifosfamide, Carboplatin.
Shares Ifosfamide, Carboplatin.
Shares Ifosfamide, Carboplatin.
Shares Ifosfamide, Carboplatin.